Amy Sharma

Join this workshop to bridge the critical gap between preclinical promise and clinical reality, where the focus shifts from molecular potency to the power of a translational data package

• Discussing ideal assays for bankable safety data beyond TCRs, such as cytokine release assays and tissue models
• Evaluating the translational impact of Fc-silencing or Fcengineering on systemic inflammation and half-life in a nonanimal context
• Discussing the current gap in translational models for ICANS/ neurotoxicity and whether specialized neuro models are ready for IND inclusion
• Deep diving into how TCE developers are harnessing the modified MABEL approach to avoid ‘sub-therapeutic’ dose escalation and save cohorts
• Discussing how unexpected clinical outcomes should trigger new in vitro or ex vivo studies